Combination of Irinotecan and Temozolomide in Children With Brain Tumors.

April 16, 2012 updated by: Pfizer

Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.

This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

83

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Westmead, New South Wales, Australia, 2145
        • Pfizer Investigational Site
    • Queensland
      • Herston, Queensland, Australia, 4029
        • Pfizer Investigational Site
    • Victoria
      • Parkville, Victoria, Australia, 3052
        • Pfizer Investigational Site
  • Belgium
      • Gent, Belgium, 9000
        • Pfizer Investigational Site
      • Leuven, Belgium, 3000
        • Pfizer Investigational Site
  • Denmark
      • Aarhus N, Denmark, 8200
        • Pfizer Investigational Site
      • Koebenhavn OE, Denmark, 2100
        • Pfizer Investigational Site
  • France
      • Angers, France, 49000
        • Pfizer Investigational Site
      • Bordeaux, France, 33000
        • Pfizer Investigational Site
      • Lille, France, 59020
        • Pfizer Investigational Site
      • Lyon Cedex 08, France, 69373
        • Pfizer Investigational Site
      • Marseille, France, 13385
        • Pfizer Investigational Site
      • Paris, France, 75005
        • Pfizer Investigational Site
      • Villejuif, France, 94805
        • Pfizer Investigational Site
  • Italy
      • Padova, Italy, 35100
        • Pfizer Investigational Site
  • Poland
      • Warszawa, Poland, 04-730
        • Pfizer Investigational Site
  • Spain
      • Barcelona, Spain, 08035
        • Pfizer Investigational Site
      • Madrid, Spain, 28009
        • Pfizer Investigational Site
      • Sevilla, Spain, 41013
        • Pfizer Investigational Site
      • Valencia, Spain, 46026
        • Pfizer Investigational Site
    • Barcelona
      • Esplugues de Llobregat, Barcelona, Spain, 08950
        • Pfizer Investigational Site
    • Murcia
      • El Palmar, Murcia, Spain, 30120
        • Pfizer Investigational Site
  • United Kingdom
      • Birmingham, United Kingdom, B4 6NH
        • Pfizer Investigational Site
      • Leeds, United Kingdom, LS9 7TF
        • Pfizer Investigational Site
      • Manchester, United Kingdom, M27 4HA
        • Pfizer Investigational Site
      • Newcastle Upon Tyne, United Kingdom, NE1 4LP
        • Pfizer Investigational Site
      • Nottingham, United Kingdom, NG7 2UH
        • Pfizer Investigational Site
      • Sutton, United Kingdom, SM2 5PT
        • Pfizer Investigational Site
    • Hampshire
      • Soouthampton, Hampshire, United Kingdom, SO16 6YD
        • Pfizer Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease.
  • Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization [WHO] grade 3 or 4)
  • Life expectancy ≥ 3 months

Exclusion Criteria:

  • Diagnosis of brainstem glioma
  • Concurrent administration of any other anti-tumor therapy
  • Pre-existing uncontrolled diarrhea

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Temozolomide + Irinotecan
Drug: Irinotecan
Irinotecan 10 mg/m^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
Drug: Temozolomide
Temozolomide 100-125 mg/m^2 daily on days 1-5 in repeated 3 week cycles

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Objective Response of Complete Response or Partial Response
Time Frame: Baseline to 1 Year (medulloblastoma), Baseline to 6 Weeks (high-grade glioma)
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR). CR persisted on repeat imaging study at least (≥) 4 weeks after initial documentation of response. PR, for bidimensionally measurable disease, was a decrease by ≥50% of the sum of the products of the largest perpendicular diameters of all measurable lesions as determined by 2 observations not less than 4 weeks apart. Best overall response recorded any time while the participant was receiving treatment. External Response Review Committee (ERRC) assessment.
Baseline to 1 Year (medulloblastoma), Baseline to 6 Weeks (high-grade glioma)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Objective Response of Complete Response or Partial Response, Investigator's Assessment
Time Frame: Baseline to 1 Year (medulloblastoma), Baseline to 6 Weeks (high-grade glioma)
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR. CR persisted on repeat imaging study ≥4 weeks after initial documentation of response. PR, in case of bidimensionally measurable disease, was a decrease by ≥50% of the sum of the products of the largest perpendicular diameters of all measurable lesions as determined by 2 observations not less than 4 weeks apart. Best overall response could be recorded any time while the participant was receiving treatment. Investigator's assessment.
Baseline to 1 Year (medulloblastoma), Baseline to 6 Weeks (high-grade glioma)
Duration of Response
Time Frame: Baseline to Date of Tumor Response (Up to 1 Year)
Median duration (50%) of tumor response for participants with objective disease response: who have not progressed or died due to any cause; with a response and subsequent progression or death due to any cause for duration of response (DR). DR was defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurred first. DR (calculated in Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7. Investigator's assessment.
Baseline to Date of Tumor Response (Up to 1 Year)
Time to Treatment Failure (TTF)
Time Frame: Baseline to Date of Treatment Failure (Up to 1 Year)
TTF was defined as the time from the date of first dose of study treatment to the date of the first documentation of progressive disease (PD), the date of treatment discontinuation except completion of treatment, or date of death due to cancer. Investigator's assessment.
Baseline to Date of Treatment Failure (Up to 1 Year)
Time to Tumor Progression (TTP)
Time Frame: Baseline to Date of Progression (Up to 1 Year)
TTP was defined as the time in months from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever came first. TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7 multiplied by 4.33. Tumor progression was determined from oncologic assessment data (where data met the criteria for PD). Investigator's assessment.
Baseline to Date of Progression (Up to 1 Year)
Overall Survival (OS)
Time Frame: Baseline to Date of Death (Up to 1 Year After Treatment)
Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7 multiplied by 4.33. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). Investigator's assessment.
Baseline to Date of Death (Up to 1 Year After Treatment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2007

Primary Completion (Actual)

January 1, 2011

Study Completion (Actual)

December 1, 2011

Study Registration Dates

First Submitted

November 27, 2006

First Submitted That Met QC Criteria

November 27, 2006

First Posted (Estimate)

November 28, 2006

Study Record Updates

Last Update Posted (Estimate)

April 18, 2012

Last Update Submitted That Met QC Criteria

April 16, 2012

Last Verified

April 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A5961166

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glioma

Clinical Trials on Irinotecan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe